NCT07357740

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	CagriSema	Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.
DRUG	Placebo CagriSema	Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Timeline

• Start date: 2026-08-27
• Primary completion: 2027-08-25
• Completion: 2027-10-13
• First posted: 2026-01-22
• Last updated: 2026-03-30

Locations

61 sites across 8 countries: United States, Denmark, Greece, Malaysia, Serbia, Slovakia, Spain, Thailand

Regulatory

• FDA-regulated drug study